Data Sheet (Cat.No.T16424)

TargetMol

p38 MAPK-IN-1

Chemical Properties



CAS No. : 1006378-90-0

Formula: C21H14F2N2O

Molecular Weight: 348.35

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.
Targets(IC50)	p38 MAPK
In vivo	Methods: p38 MAPK-IN-1 (1 mg/kg, intravenous injection and; 10 mg/kg, oral administration) was administered to male wistar rats for in vivo pharmacokinetic study. Results: p38 MAPK-IN-1 had a t1/2 of 7.4 hours and an intravenous CL of 2.7 mL/min/kg. The Cmax of p38 MAPK-IN-1 in male wistar rats after oral administration was 5.3 μM. [1]

Solubility Information

Solubility	DMSO: 20 mg/mL (57.41 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8707 mL	14.3534 mL	28.7068 mL
5 mM	0.5741 mL	2.8707 mL	5.7414 mL
10 mM	0.2871 mL	1.4353 mL	2.8707 mL
50 mM	0.0574 mL	0.2871 mL	0.5741 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Lumeras W, et al. 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase. J Med Chem. 2011 Nov 24;54(22):7899-910.

Wang Q, et al. S100A9 promotes renal calcium oxalate stone formation via activating the TLR4-p38/MAPK-LCN2 signaling pathway. Int J Biol Macromol. 2024 Nov;281(Pt 1):136178.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481